ROCKAWAY, NJ , Aug. 10, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, “Transcutaneous Cervical Vagal Nerve Stimulation (tcVNS/nVNS) in Patients with Posttraumatic Stress
Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a foreign language compared to sham while simultaneously showing improved focus and decreased fatigue in study participants ROCKAWAY, N.J. , April 24, 2023 (GLOBE NEWSWIRE) -- electroCore,
ROCKAWAY, N.J. , June 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air
A study published in the Journal of Headache and Pain, carried out by Dr. Thomas Kinfe of the University of Bonn, found that twice daily stimulation of the vagus nerve with the hand-held gammaCore nVNS device reduced the number of headache days per month from 14.7 to 8.9 (p